Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …

With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …

Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …

Background Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 …

Background The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic hinges on virus evolution and duration of immune protection of natural infection …

Importance The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly
understood. Objective To assess protection from SARS-CoV-2 breakthrough infection after …

Background Long-term effectiveness of COVID-19 mRNA boosters in populations with different
previous infection histories and clinical vulnerability profiles is inadequately understood. …

The overarching objective of this study was to provide the descriptive epidemiology of the
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by …